Accelerating Regulatory Review of Medical Products

Long and unpredictable regulatory review can delay promising medicines, vaccines, and other medical products from reaching people who need them. Through institutional strengthening, policy development, and capacity-building efforts, 1Day Sooner works to help regulators make high-quality decisions faster while maintaining rigorous standards for safety and effectiveness.

We believe artificial intelligence can become an important part of this effort. AI-enabled tools have the potential to support regulatory workflows, including dossier review, evidence synthesis, information management, and post-market surveillance. To benefit from the upcoming age of transformative AI, regulators need appropriate governance frameworks, digital infrastructure, technical expertise, and systems for evaluating and assuring the performance of AI tools.

1Day Sooner has advocated for the responsible use of AI to strengthen regulatory review, including at the U.S. Food and Drug Administration. Through our African chapter, 1Day Africa, we are also working with the African Medicines Agency (AMA) and national regulatory authorities across the continent to explore how AI can be responsibly integrated into medicines regulation. Our work focuses on regulatory information management systems, AI governance and policy, institutional capacity, and the technical and organizational foundations needed for AI-assisted regulatory review.


General Questions

 

CHIMs

 

AI in medicines regulation

 

Other questions